For example, IMP-321, an APC activator targeting LAG3, has been clinically tested in metastatic RCC.[33] Although immune checkpoint inhibitors have demonstrated significant benefits against RCC, they have some drawbacks. This evidence concerns the gene APC and renal cell carcinoma.